Orchestra BioMed director granted 42,553 stock options

Orchestra BioMed Holdings director Aryeh Jason received a new stock option grant.

Rhea-AI Filing Summary

Orchestra BioMed Holdings director Aryeh Jason received a new stock option grant. The award covers 42,553 options to buy Common Stock at an exercise price of $4.04 per share, with no cash paid at grant.

The options were granted on June 23, 2026 and will vest on the one-year anniversary of the June 23, 2026 grant date, as long as Jason continues to serve the company through that date. After this award, he holds 42,553 options directly, and there were no share sales or open-market purchases reported in this filing.

Insights

Equity compensation analyst

Routine director option grant adds equity incentive without immediate cash impact.

This filing shows Aryeh Jason, a director of Orchestra BioMed Holdings, receiving 42,553 stock options at an exercise price of $4.04 per share. The grant carries a zero purchase price today and only has value if the stock trades above the exercise price.

The options vest on the one-year anniversary of the June 23, 2026 grant date, contingent on continuous service. This structure is typical for director compensation, aligning incentives with shareholders over time rather than indicating any active buying or selling in the market.

Insider Trade Summary

Grant/Award: 42,553 shares

Grant/Award 1 txn

Insider Aryeh Jason

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	42,553	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 42,553 contracts (Direct)

Footnotes (1)

1. F1. The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.

Key Figures

Options granted: 42,553 options Exercise price: $4.04 per share Total options after grant: 42,553 options +3 more

6 metrics

Options granted 42,553 options Stock Option (Right to Buy) granted to director on June 23, 2026

Exercise price $4.04 per share Conversion or exercise price of stock options

Total options after grant 42,553 options Total derivative securities owned following transaction

Grant date June 23, 2026 Option grant (transaction) date

Expiration date June 23, 2036 Option expiration for the stock option grant

Grant price $0.00 per option Price paid at grant for the stock options

Key Terms

Stock Option (Right to Buy), Grant Date, Common Stock, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant Date financial

"anniversary of June 23rd, 2026 (the "Grant Date")"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 4.0400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What did Aryeh Jason receive in this Orchestra BioMed (OBIO) Form 4 filing?

Aryeh Jason received a grant of 42,553 stock options for Orchestra BioMed common stock. These options give him the right to buy shares at a fixed exercise price of $4.04 per share in the future, subject to vesting conditions tied to continued service.

What is the exercise price of the new OBIO stock options granted to Aryeh Jason?

The new stock options granted to Aryeh Jason have an exercise price of $4.04 per share. This means he can buy Orchestra BioMed common stock at $4.04 once the options vest, if the market price is higher and he chooses to exercise.

When do Aryeh Jason’s Orchestra BioMed stock options vest?

The stock options will vest on the one-year anniversary of the June 23, 2026 grant date. Vesting is conditioned on Aryeh Jason’s continuous service with Orchestra BioMed through that anniversary, so he must remain in his role until then to receive the benefit.

Did Aryeh Jason buy or sell any Orchestra BioMed (OBIO) shares in this transaction?

No open-market share purchases or sales occurred in this transaction. The Form 4 reports a compensation-related grant of 42,553 stock options with a $4.04 exercise price, not a market trade, so it does not directly change the public share float.

How many Orchestra BioMed options does Aryeh Jason hold after this grant?

After this grant, Aryeh Jason holds 42,553 stock options directly. These options relate to an equivalent number of underlying Orchestra BioMed common shares and are subject to vesting and the $4.04 per share exercise price described in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PENNSYLVANIA 18938

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.04	06/23/2026		A		42,553		(1)	06/23/2036	Common Stock	42,553	$0	42,553	D

Explanation of Responses:

1. The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.

	/s/ Andrew Taylor, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)